FindTrial
Sign In

Real world outcome research of the patients with acute lymphoblastic leukemia treated with Inotuzumab ozogamicin

Real world outcome research of the patients with acute lymphoblastic leukemia treated with Inotuzumab ozogamicin

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0010009
Enrollment
100
Registered
2024-12-06
Start date
2020-11-04
Completion date
Unknown
Last updated
2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

The Catholic University of Korea, Seoul St. Mary's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Age Criteria: Adults aged 19 years to 74 years old 2) Diagnosed with acute lymphoblastic leukemia (ALL) and identified as having relapsed or refractory disease due to lack of response to prior treatment. 3) Patients who have undergone salvage chemotherapy with inotuzumab ozogamicin.

Exclusion criteria

Exclusion criteria: 1) Age under 19 years old

Design outcomes

Primary

MeasureTime frame
Overall Response (CR+CRi+CRp) rate—

Secondary

MeasureTime frame
Overall Survival;Transplantation proceeding rate;Minimal residual disease rate;Incidence of hepatic veno-occlusive disease—

Countries

Korea, Republic of

Contacts

Public ContactJae-Ho Yoon

The Catholic University of Korea, Seoul St. Mary's Hospital

royoon@catholic.ac.kr+82-2-2258-6270

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026